BioSpace News Archive

UroGen Pharma today announced financial results for the first quarter ended March 31, 2021 and provided an overview of the Company’s recent developments.

- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 following FDA guidance - Announced a collaboration with the Celiac Disease Foundation (CDF) to support clinical trial enrollment in 9 Meters Phase 3 study,

CureVac N.V. announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the Canaccord Musculoskeltal Conference on Thursday, May 20, 2021, at 3:00 PM Eastern Time.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat at the Truist Securities Life Sciences Summit at 1:00 pm ET on Monday, May 17, 2021.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces the filing of its SEC Form 10-Q (quarterly report), for the quarter ended March 31, 2021.

Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that in connection with the Company’s previously disclosed succession plan: Leonard Osser announced his intention to resign as Interim Chief Executive Officer

Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs, announced that it has filed its 2021 first quarter report. The Report shows that the Company had Cash & Cash Equivalents of $1,796,596 as of March 31, 2021, the period end.

Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that an abstract highlighting positive data from the EQUATE study of itolizumab in acute graft-versus-host disease has been accepted for oral presentation at EHA2021 Virtual Congress.

Heron Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved ZYNRELEF